Truncated-CRMP4 by calpain-2 suppresses CRMP4 to promote metastasis of prostate cancer via promoter methylation through E2F1/NF-?B/DNMT1 signaling
Sources of Funding: This work was supported by National Natural Science Foundation of China (81372728, 81572503).
Introduction
Metastasis is the primary cause of cancer-specific death in patients with prostate cancer (PCa). Previous studies identified promoter methylation is responsible for the repression of the tumor metastasis-suppressor gene collapsing response mediator protein-4 (CRMP4) in metastatic PCa. However, the underlying mechanisms for promoter methylation remain unknown.
Methods
In this study, calpain-2 expression in prostatic benign and cancer tissues was determined using immunohistochemistry (IHC). The effects of truncated-CRMP4 by calpain-2 in migration and invasion of PCa cells and the underlying mechanisms were explored. The role of nuclear factor-kappaB (NF-kB) in CRMP4 promoter methylation was evaluated. In addition, the downstream signaling regulated by CRMP4 were determined.
Results
Calpain-2 was differentially upregulated in metastatic PCa Calpain-2 was differentially upregulated in metastatic PCa tissues. N-terminally truncated-CRMP4 by calpain-2 enhanced the ability of migration and invasion via nuclear translocation and subsequently activation of E2F1-mediated DNA methyltransferase 1 (DNMT1) expression. In addition, NF-kB RelA/p65 recruited DNMT1 to directly bind to and methylate the CRMP4 promoter in which Serine276 phosphorylation of p65 was essential. Furthermore, CRMP4 CRMP4 exhibited anti-metastatic function by inhibiting the expression of vascular endothelial growth factor C (VEGFC) via Sema3B- Neuropilin2 signaling.
Conclusions
Calpain-mediated cleavage of CRMP4 promotes PCa metastasis by suppression of CRMP4 transcription via nuclear translocation of N-terminally truncated fragment and subsequent activation of E2F1/NF-kB/DNMT1 signaling which in turn enhanced CRMP4 promoter hypermethylation. Targeting re-expression of CRMP4 may be of great significance in the treatment of patients with metastatic PCa.
Funding
This work was supported by National Natural Science Foundation of China (81372728, 81572503).
Yunhua Mao
Zheng Chen
Jun Pang
Ke Li